Modified ionic liquid cold-induced aggregation dispersive liquid-liquid microextraction combined with spectrofluorimetry for trace determination of ofloxacin in pharmaceutical and biological samples

ABSTRACT

Ofloxacin is a quinolone synthetic antibiotic, which acts against resistant mutants of bacteria by inhibiting DNA gyrase. This antibacterial agent is widely used in the treatment of respiratory tract, urinary tract and tissue-based infections, which are caused by Gram-positive and Gram-negative bacteria. In this work, an efficient modified ionic liquid cold-induced aggregation dispersive liquid-liquid microextraction [M-IL-CIA-DLLME] was combined with spectrofluorimetry for trace determination of ofloxacin in real samples. In this microextraction method, hydrophobic l-hexyl-3-methylimidazolium hexafluorophosphate [[Hmim] [PF[6]]] ionic liquid [IL] as a microextraction solvent was dispersed into a heated sample solution containing sodium hexafluorophosphate [NaPF[6]] [as a commonion]] and the analyte of interest. Afterwards, the resultant solution was cooled in an ice-water bath and a cloudy condition was formed due to a considerable decrease of IL solubility. After centrifuging, the enriched phase was introduced to the spectrofluorimeter for the determination of ofloxacin. In this technique, the performance of the microextraction method was not influenced by variations in the ionic strength of the sample solution [up to 30% w/v]. Furthermore, [Hmim][PF[6]] IL was chosen as a green microextraction phase and an alternative to traditional toxic organic solvents. Different parameters affecting the analytical performance were studied and optimized. At optimum conditions, a relatively broad linear dynamic range of 0.15-125 microg I[-1] and a limit of detection [LOD] of 0.029 microg I[-1] were obtained. The relative standard deviation [R.S.D.] obtained for the determination of five replicates of the 10 ml solution containing 50 ug I"1 ofloxacin was 2.7%. Finally, the combined methodology was successfully applied to ofloxacin determination in actual pharmaceutical formulations and biological samples